Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy

Overview

Journal Nanomicro Lett

Publisher Springer

Date 2021 Jun 17

PMID 34138315

Citations 21

Authors

Qinjun Chen

Tao Sun

Chen Jiang

Affiliations

Soon will be listed here.

Abstract

Although current anticancer immunotherapies using immune checkpoint inhibitors (ICIs) have been reported with a high clinical success rate, numerous patients still bear 'cold' tumors with insufficient T cell infiltration and low immunogenicity, responding poorly to ICI therapy. Considering the advancements in precision medicine, in-depth mechanism studies on the tumor immune microenvironment (TIME) among cold tumors are required to improve the treatment for these patients. Nanomedicine has emerged as a promising drug delivery system in anticancer immunotherapy, activates immune function, modulates the TIME, and has been applied in combination with other anticancer therapeutic strategies. This review initially summarizes the mechanisms underlying immunosuppressive TIME in cold tumors and addresses the recent advancements in nanotechnology for cold TIME reversal-based therapies, as well as a brief talk about the feasibility of clinical translation.

Citing Articles

Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma.

Zou J, Han W, Hu Y, Zeng C, Li J, Lei W World J Surg Oncol. 2025; 23(1):16.

PMID: 39844176 PMC: 11752792. DOI: 10.1186/s12957-025-03680-x.

Predictive value of dendritic cell-related genes for prognosis and immunotherapy response in lung adenocarcinoma.

Sun Z, Hu M, Huang X, Song M, Chen X, Bei J Cancer Cell Int. 2025; 25(1):13.

PMID: 39810206 PMC: 11730157. DOI: 10.1186/s12935-025-03642-z.

Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors.

Pavelescu L, Enache R, Rosu O, Profir M, Cretoiu S, Gaspar B Int J Mol Sci. 2024; 25(17).

PMID: 39273605 PMC: 11395316. DOI: 10.3390/ijms25179659.

Breast Cancer Treatment Strategies Targeting the Tumor Microenvironment: How to Convert "Cold" Tumors to "Hot" Tumors.

Yang L, Hu Q, Huang T Int J Mol Sci. 2024; 25(13).

PMID: 39000314 PMC: 11241188. DOI: 10.3390/ijms25137208.

Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy.

Moon Y, Cho H, Kim K Pharmaceutics. 2024; 16(6).

PMID: 38931916 PMC: 11207855. DOI: 10.3390/pharmaceutics16060795.

References

Knudsen K, Northeved H, Kumar P, Permin A, Gjetting T, Andresen T . In vivo toxicity of cationic micelles and liposomes. Nanomedicine. 2014; 11(2):467-77. DOI: 10.1016/j.nano.2014.08.004. View

Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuchel R, Kiessling F . Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325. PMC: 7115878. DOI: 10.1016/j.addr.2019.01.005. View

Sun D, Ma J, Wang J, Zhang F, Wang L, Zhang S . Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort. Ther Clin Risk Manag. 2018; 14:1691-1700. PMC: 6140734. DOI: 10.2147/TCRM.S173041. View

Min Y, Caster J, Eblan M, Wang A . Clinical Translation of Nanomedicine. Chem Rev. 2015; 115(19):11147-90. PMC: 4607605. DOI: 10.1021/acs.chemrev.5b00116. View

Song W, Shen L, Wang Y, Liu Q, Goodwin T, Li J . Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun. 2018; 9(1):2237. PMC: 5993831. DOI: 10.1038/s41467-018-04605-x. View

Traini G, Ruiz-de-Angulo A, Blanco-Canosa J, Bascaran K, Molinaro A, Silipo A . Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1. Small. 2018; 15(4):e1803993. DOI: 10.1002/smll.201803993. View

Cheng W, Ho P . Firing Up Cold Tumors. Trends Cancer. 2019; 5(9):528-530. DOI: 10.1016/j.trecan.2019.06.005. View

Chen B, Dai W, He B, Zhang H, Wang X, Wang Y . Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics. 2017; 7(3):538-558. PMC: 5327631. DOI: 10.7150/thno.16684. View

Emadi A, Jones R, Brodsky R . Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009; 6(11):638-47. DOI: 10.1038/nrclinonc.2009.146. View

10.

Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M . Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10(8):858-64. DOI: 10.1038/nm1075. View

11.

Brogi E, Wu T, Namiki A, Isner J . Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994; 90(2):649-52. DOI: 10.1161/01.cir.90.2.649. View

12.

Bogdan C . Nitric oxide and the immune response. Nat Immunol. 2001; 2(10):907-16. DOI: 10.1038/ni1001-907. View

13.

Schmid M, Avraamides C, Dippold H, Franco I, Foubert P, Ellies L . Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011; 19(6):715-27. PMC: 3144144. DOI: 10.1016/j.ccr.2011.04.016. View

14.

Sun T, Zhang G, Wang Q, Guo Z, Chen Q, Chen X . Pre-blocked molecular shuttle as an in-situ real-time theranostics. Biomaterials. 2019; 204:46-58. DOI: 10.1016/j.biomaterials.2019.02.019. View

15.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

16.

Wang Z, Zhang F, Shao D, Chang Z, Wang L, Hu H . Janus Nanobullets Combine Photodynamic Therapy and Magnetic Hyperthermia to Potentiate Synergetic Anti-Metastatic Immunotherapy. Adv Sci (Weinh). 2019; 6(22):1901690. PMC: 6864517. DOI: 10.1002/advs.201901690. View

17.

Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H . Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 2017; 108(10):1947-1952. PMC: 5623748. DOI: 10.1111/cas.13332. View

18.

Chen C, Ni X, Jia S, Liang Y, Wu X, Kong D . Massively Evoking Immunogenic Cell Death by Focused Mitochondrial Oxidative Stress using an AIE Luminogen with a Twisted Molecular Structure. Adv Mater. 2019; 31(52):e1904914. DOI: 10.1002/adma.201904914. View

19.

Hildenbrand R, Dilger I, Horlin A, STUTTE H . Urokinase and macrophages in tumour angiogenesis. Br J Cancer. 1995; 72(4):818-23. PMC: 2034060. DOI: 10.1038/bjc.1995.419. View

20.

Minchinton A, Tannock I . Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. DOI: 10.1038/nrc1893. View